The release of a Category III CPT code provides a critical pathway to reimbursement for Perthera’s AI-assisted decision support tool for oncologists.

MCLEAN, VA, UNITED STATES, February 8, 2023 /EINPresswire.com/ -- Perthera.ai, the industry leader in Oncology Decision Support, announces the release by the American Medical Association of a new Current Procedural Terminology (CPT) Category III code, 0794T, clearly recognizing the increasing importance of AI-assisted decision support in delivering precision oncology care. Perthera.ai is a pioneer in personalized AI-assisted Oncology decision support with its patented ranked therapy options presented in the Perthera Report created by our Precision Oncology Platform.

Perthera.ai’s patented process provides physicians with an easy-to-use report with therapy options ranked by a unique approach combining existing evidence, real-world evidence (RWE), a patient’s past medical and treatment history, and their multi-omic molecular profile. The Perthera.ai approach to Precision Oncology combines AI capabilities with “humans in the loop” using a Virtual Molecular Tumor Board of disease-specific experts to further refine ranked options for every single patient. As new information becomes available for the patient, an updated report can be generated, providing ongoing therapy decision support to the physician as the patient goes through their unique cancer journey.

CPT codes are created and maintained by the AMA CPT Editorial Panel. They are used by government payers, including Medicare, Medicaid, and commercial health plans to identify healthcare services and procedures that are eligible for reimbursement. Category III CPT codes apply to emerging technologies. They are valid for at least five years to measure both utilization and unique benefits, at which time the AMA may award a Category I CPT Code. Category III CPT codes are an important milestone for FDA approval and payment negotiations. This new CPT code will go into effect on July 1, 2023.

“The issuance of this CPT code provides a critical pathway to reimbursement and allows Perthera.ai to continue its mission to define excellence and scientific rigor in clinically useful, AI-assisted Oncology decision support,” said Albert Kelley, President and CEO of Perthera.ai. "We continue to improve and perfect our industry-defining patented process that provides doctors and patients with evidence-based options based on not only the genomic and molecular findings but also taking into account prior therapy and the essential addition of expert review via our unique asynchronous Virtual Molecular Tumor Board,” said Emanuel “Chip” Petricoin, Ph.D., Chief Science Officer and Co-Founder of Perthera.ai.

About Perthera.ai

Perthera.ai pioneers using “multi-omic” test results (DNA, RNA, IHC, and phosphoproteomics) to advise doctors and patients on treatment options through our Precision Oncology Platform and the Perthera Report it generates. We collect past medical and treatment history along with multi-omic results from any source and use our proprietary Ranked Therapy Options process to identify the best treatments available for each patient. Uniquely, we follow patients longitudinally to obtain real world outcomes that further inform our recommendations. The Perthera Precision Oncology Platform has been validated through peer-reviewed, high-impact journal publications. It has been shown clinically to increase survival rates for patients with pancreatic cancer who had actionable findings and followed its matched therapies. We are determined to make Perthera’s Precision Oncology Platform and the Perthera Report the best resource available today for Oncologists in their treatment decision-making process.

Albert Kelley
Perthera.ai
+1 703-286-0780
email us here
Visit us on social media:
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.